Fully Human Antibodies, Acceleration of Discovery & Development

Mission

Innovation Award for CORAT’s COVID-19 antibody development
The CORAT consortium, a cooperation between Braunschweig University and YUMAB GmbH has received the Innovation Award of the State of Lower Saxony for its collaborative fast track development of therapeutic COVID-19 antibodies. Read press release

Breaking News

Individual Project Design, Fee for Service or Milestone-based

Contract Research, R&D Services

Innovation Award for CORAT’s COVID-19 antibody development
The CORAT consortium, a cooperation between Braunschweig University and YUMAB GmbH has received the Innovation Award of the State of Lower Saxony for its collaborative fast track development of therapeutic COVID-19 antibodies. Read press release

Breaking News

Partnered R&D, Collaborations, Licensing

Pipeline & Partnering

Innovation Award for CORAT’s COVID-19 antibody development
The CORAT consortium, a cooperation between Braunschweig University and YUMAB GmbH has received the Innovation Award of the State of Lower Saxony for its collaborative fast track development of therapeutic COVID-19 antibodies. Read press release

Breaking News

YUMAB® – Company

YUMAB is a world leading provider of contract research, technologies, and R&D services for the development of fully human, therapeutic antibodies. The YUMAB® platform is based on almost 30 years of continuous research by its founders in antibody discovery and engineering. It combines state of the art and next generation technologies from target to lead under one roof. YUMAB offers individually designed projects and business solutions for small biotech start-ups up to large biopharma companies.

News & Events

Innovation Award for CORAT Consortium
September 28, 2020
The CORAT consortium, a cooperation between Braunschweig University and YUMAB GmbH has received the Innovation Award of the State of Lower Saxony for its efforts in the collaborative fast track development of therapeutic COVID-19 antibodies.
Read more

First SARS-CoV-2 neutralizing antibody discovered
May 07, 2020
YUMAB’s human SARS-CoV-2 antibody candidate exhibits a coronavirus neutralizing effect, as confirmed in preclinical tests with COVID-19 patient sera at the Helmholtz Center for Infection Research.
Read more

Coronavirus statement
March 20, 2020
YUMAB is committed to uphold its business activities during times of the coronavirus pandemic.
Read more

Proteins & Antibodies Congress
April 27-29, 2020
Meet Philipp Kuhn to discuss your needs in antibody development and engineering.
Read more

Enleofen enters joint development with Boehringer Ingelheim
January 09, 2020
YUMAB partner Enleofen joins forces with Boehringer Ingelheim to develop novel anti-IL-11 therapies for a range of fibrotic diseases.
Read more

CRO / R&D Services

YUMAB offers contract research, technologies and R&D services for the discovery and development of fully human, therapeutic antibodies.

YUMAB® Platform, Partnering

YUMAB also provides partnering and collaboration strategies to provide access to our technologies and expertise for academic spin-offs and start-up companies without the burden of technology access fees.

Contact

SEND US AN E-MAIL

YUMAB GMBH

Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany

Phone: (+49) 531-481170-0
Email: info@yumab.com

YUMAB Inc.

1100 South Tower
225 Peachtree Street NE
Atlanta, GA 30303 – USA

Phone: (+49) 531 481170-0
Email: info@yumab.com

Breaking News

Breaking News

Breaking News

Breaking News

YUMAB® – Company

News & Events

CRO / R&D Services

YUMAB® Platform, Partnering

Bioinformatic Optimizations

The Power of in vitro Selection

Fully Human Therapeutic Antibodies

Antibody Engineering

Nature-derived Antibody Libraries

YUMAB® – Versatile Platform Concept

Contact

SEND US AN E-MAIL

YUMAB GMBH

YUMAB Inc.

YUMAB GmbH

More Information

Cookie and Privacy Settings